Skip to main content

Notable number of patients taking immune checkpoint inhibitors hospitalized with irAEs

Doctor_hospital bed

Patients receiving immune checkpoint inhibitor treatment have an increased risk for being hospitalized with immune-related adverse events, particularly if they are older or taking combination treatments, researchers report.


Global RA burden ‘significant, yet under-recognized’

Stethoscope and globe

Almost 20 million people worldwide were living with rheumatoid arthritis in 2017, with over a million new cases diagnosed each year, according to estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study.


Monocyte counts could predict IPF outcome


Elevated monocyte counts are associated with poor outcomes among patients with idiopathic pulmonary fibrosis, suggest study findings published in The Lancet Respiratory Medicine.

Headlines from across medwireNews

20-09-2019 | Rheumatology | News | Article

Multiple modifiable risk factors impact post hip replacement dislocation risk

Dislocation risk following total hip replacement is declining with time and is associated with a number of surgical, hospital, and patient-related factors that are generally modifiable, UK researchers report.

20-09-2019 | Diabetes | News | Article

Mixed results for PRIORITY diabetic nephropathy trial

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

20-09-2019 | Oncology | News | Article

Adding carboplatin to cabazitaxel benefits men with mCRPC

Phase I/II research published in The Lancet Oncology shows that combining cabazitaxel with carboplatin has the potential to prolong progression-free survival in men with metastatic castration-resistant prostate cancer.

19-09-2019 | News | Article

Majority of MDI users improve glycemic outcomes with CGM

Analysis of the GOLD study suggests that at least three-quarters of people with type 1 diabetes using multiple daily injections benefit from continuous glucose monitoring.

19-09-2019 | Rheumatology | News | Article

IL-1 inhibition may benefit for people with RA, type 2 diabetes

Treatment with the interleukin-1 inhibitor anakinra improves both glycemic and inflammatory endpoints among patients with rheumatoid arthritis and type 2 diabetes, suggest findings from the TRACK trial.

19-09-2019 | Diabetes | News | Article

Imeglimin shows promise for type 2 diabetes

Imeglimin, an agent that improves mitochondrial function, has demonstrated potential as a novel treatment option for Japanese patients with type 2 diabetes in the phase III TIMES 1 and TIMES 3 trials.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.

Meet the team

Image Credits